Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Migraine And Increased Risk Of Cardiovascular Disease: Migraine Frequency Plays A Role
Women who have migraines with aura may be more likely to have a stroke or heart attack than women who don"t have the condition, and the association varies by migraine frequency, according to research published in the June 24, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology. An aura is a visual or other sensory disturbance that occurs before the migraine starts, such as seeing bright lights.

New Medicare Nursing Home Guidance To Include Quality Of Life And Environment Requirements
The Centers for Medicare & Medicaid Services (CMS) issued new guidance for nursing home surveyors, further defining and clarifying several important dimensions of care to help improve nursing home residents" quality of life and environment.
News of the day
HESA Performance Indicators Show That 1994 Group Universities Are 'elite But Not Elitist'
1994 Group universities are continuing to widen access to higher education, attracting over 4/5 of their students from state schools for a third consecutive year, as highlighted by statistics published by the Higher Education Statistics Agency (HESA.) As well as increasing their average percentage of entrants from state schools by three times the national average, 1994 Group universities have also achieved drop-out rates well below the sector-wide average for a forth year running, signalling that wider participation and high quality student experience can go hand in hand.
Medical Devices

FDA Approves Multaq To Treat Heart Rhythm Disorder

The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat. Multaq may cause critical adverse reactions, including death, in patients with recent severe heart failure. The drug"s label will contain a boxed warning, the FDA"s strongest warning, cautioning that the drug should not be used in severe heart failure patients. "Multaq represents a therapeutic innovation for treatment of the heart rhythm disorder of atrial fibrillation," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA"s Center for Drug Evaluation and Research. In a multinational clinical trial with more than 4,600 patients, Multaq reduced cardiovascular hospitalization or death from any cause by 24 percent, when compared with an inactive pill (placebo). Most of that effect represents reduced hospitalizations, especially hospitalizations related to atrial fibrillation. Atrial fibrillation and atrial flutter cause the heart to beat abnormally fast and sometimes prevent blood from being properly pumped out of the heart. The most common adverse reactions reported by patients in clinical trials were diarrhea, nausea, vomiting, fatigue and loss of strength. Multaq is manufactured by Paris-based sanofi-aventis. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009